SCHEMBL1705015

SCHEMBL1705015

CCCCNC1CCC(Oc2cc3ccncc3cc2Cl)CC1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 14/20 0.44
ROCK1 Q13464 5/20 0.43
ROCK2 O75116 2/20 0.43
CHUK O15111 10/20 0.42
LCK P06239 2/20 0.40
AKT1 P31749 1/20 0.36
SUV39H2 Q9H5I1 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
LIMK1 P53667 1/20 0.35
LIMK2 P53671 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1705786 1.00 IKBKB (0.44) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705013 1.00 IKBKB (0.44) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705039 0.94 ROCK1 (0.49) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705804 0.94 ROCK1 (0.49) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705043 0.94 ROCK1 (0.49) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705131 0.89 IKBKB (0.47) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705126 0.89 IKBKB (0.47) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705064 0.86 IKBKB (0.42) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705065 0.86 IKBKB (0.42) IKBKBROCK1ROCK2CHUKLCK
SCHEMBL1705728 0.86 IKBKB (0.42) IKBKBROCK1ROCK2CHUKLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US claimed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP claimed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
EP-2125746-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES Sanofi-Aventis (FR) 2009-12-02 EP disclosed
WO-2008077554-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives MYLK2, MYLK, MYLK3 IKBKB 1991/4885ROCK1 8/4885ROCK2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.